Timothy Jennings, DO
Family Medicine · Maryland Heights, MONPI 1548233455
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,401 of the $5,941 with a category attached, or 74.1%. 11 manufacturers reported payments, led by Pfizer at 29.9% of the total. Among family medicine clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 108 payments — averaging $55.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2K
- AbbVie$2K
- Novo Nordisk$895
- AstraZeneca$618
- Biohaven Pharmaceuticals, Inc.$353
- Biohaven Pharmaceutical Holding Company Ltd.$249
- plus $515 from 5 others
Across 967 payments — averaging $31,267 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$25.5M
- Modernatx, Inc.$2.1M
- Eli Lilly$1.2M
- Eisai Inc.$956K
- AstraZeneca$485K
- Amarin Pharma, Inc.$3K
- plus $2K from 1 others
What the payments were for
- Travel & lodging$1,52026%
- Food & beverage$4,40174%
- Gifts$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 14 | $1,775 |
| AbbVie(2 entities) | 60 | $1,535 |
| Novo Nordisk | 15 | $895 |
| AstraZeneca | 4 | $618 |
| Biohaven Pharmaceuticals, Inc. | 5 | $353 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $249 |
| Merck | 2 | $210 |
| Phathom Pharmaceuticals, Inc. | 1 | $125 |
| Amarin Pharma, Inc. | 1 | $104 |
| Exact Sciences | 3 | $48 |
| E.r. Squibb & Sons, L.L.C. | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,941 in reported general payments places this provider in the 90th percentile of 2,203 family medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 115 | $76,793 |
| EliquisApixaban | 88 | $64,343 |
| RybelsusSemaglutide | 47 | $50,200 |
| OzempicSemaglutide | 32 | $30,173 |
| FarxigaDapagliflozin Propanediol | 27 | $30,125 |
| XareltoRivaroxaban | 23 | $18,749 |
| LinzessLinaclotide | 12 | $9,941 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $8,414 |
| InvokanaCanagliflozin | 12 | $8,070 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $6,387 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $6,050 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 23 | $4,939 |
| SynthroidLevothyroxine Sodium | 34 | $4,091 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $3,482 |
| Atorvastatin Calcium | 502 | $3,293 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $895 | $80,37379 claims |
| PfizerEliquis, Abrysvo | $1,775 | $67,031100 claims |
| AstraZenecaFarxiga | $618 | $30,12527 claims |
| AbbVieLinzess, Synthroid | $1,535 | $14,03246 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Maryland Heights
- Stephen AdamsSpringfield$636K
- Justin PuckettKirksville$568K
- Matthew BeckerditeOfallon$225K
- Roger CadySpringfield$175K
- James LasalleExcelsior Springs$130K
- Matthew TiefenbrunnSullivan$105K
- Ayobami OduwoleGrandview$92K
- Michael DonovanSaint Louis$78K
- Blair ThedingerKansas City$71K
- Christine MooreRaymore$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.